Healthcare
Diagnostics & Research
$200.81B
122K
Key insights and themes extracted from this filing
The company's revenue decreased to $42.857 billion in 2023 from $44.915 billion in 2022, a 5% decline. This decrease is primarily due to reduced demand for COVID-19 related products.
GAAP operating income margin decreased to 16.0% in 2023 from 18.7% in 2022. This decline is primarily due to lower COVID-19 related revenue, partially offset by productivity improvements.
Adjusted earnings per share decreased to $21.55 in 2023 from $23.24 in 2022. This decline reflects the decrease in revenue and operating income.